First-Ever Commercially Available COVID-19 Seroconversion Panel to Confirm Presence of Anti-SARS-CoV-2 Antibodies Completed

The panel illustrates the onset and decline of IgM, IgG and Ig total SARS-CoV-2 virus antibody titers over a period of 87 days. The COVID-19 seroconversion panel was tested against enzyme-linked immunosorbent assays (ELISA) and chemiluminescent assays (CLIA) to track anti-SARS-CoV-2 antibody generation over time.

Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without the independent data to help assess their analytical performance and enable comparisons between different testing methods. With Access Biologicals' seroconversion panel, diagnostic manufacturers, clinical laboratories and researchers will have a reliable benchmark against which they can develop, validate and troubleshoot other COVID-19 serological assays and testing. The COVID-19 seroconversion panel has already been included as an assessment tool for commercial COVID-19 serological diagnostic kits in a US Centers for Disease Control and Prevention (CDC) project. Access Biologicals plans to have further discussions with the CDC to find ways to use it in the convalescent-plasma development research field.

"An effective, sensitive and specific way to identify and confirm the SARS-CoV-2 infection is urgently needed," said Mike Crowley, Managing Director Access Biologicals. "Our COVID-19 seroconversion panel will help serological assays bridge the gap through precise validation, establishing sensitivity and helping determine the pre-seroconversion window period, which is the time after infection and before seroconversion, when antibodies appear."

Related Links:
Access Biologicals